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ABSTRACT
INTRODUCTION: The diagnosis of Parkinson’s disease (PD) is 
typically based on the presence of motor symptoms, but in 
the early phase of the disease, the diagnostic process can 
be challenging. Examination of non-motor symptoms in pa-
tients suspected of PD has gained growing attention. Olfac-
tory tests have shown promising results as ancillary diag-
nostic tests. The aim of this study was to investigate how 
olfactory tests may be used clinically in diagnostic process 
in PD. 
METHODS: A systematic search was conducted in PubMed 
for relevant literature on 8 March 2017. A total of 358 ar-
ticles were found. Our screening process left 27 articles, 
which were included for further analysis. 
RESULTS: In all, 20 of the included studies analysed the di-
agnostic value of olfactory testing by comparing patients 
with PD to healthy controls. Sensitivities varied from 61% to 
95% and specificities from 66% to 99%. Ten studies used ol-
factory tests to distinguish between PD and diseases that 
mimic PD. The sensitivities varied from 62% to 92% and the 
specificities from 65% and 96%. 
CONCLUSIONS: Olfactory test can be a valuable ancillary 
tool in the diagnostic process in PD. In a clinical setting, the 
identification part from Sniffin’ Sticks 16 is the most usable 
because it may be conducted quickly and independently of 
disease duration and severity. Before using an olfactory test 
in a clinical setting, it is necessary to adjust the odours to 
the patient population, and to establish the optimal speci-
ficity-adjusted cut-off.
Parkinson’s disease (PD) is the second-most common 
neurodegenerative disease. It is characterised by tremor 
at rest, bradykinesia, rigidity and postural instability [1]. 
In addition to the motor symptoms, PD patients suffer 
from a wide range of non-motor symptoms, one of the 
most frequent of which is olfactory dysfunction. Studies 
have reported that olfactory dysfunction is present in 
approximately 90% of early-stage PD cases and that it 
may precede the onset of motor symptoms by years [2]. 
The diagnostic process of PD can be challenging,  
especially in the early phase of disease. Atypical 
Parkinsonian syndrome, including progressive supranu-
clear palsy (PSP), multiple system atrophy (MSA) and 
corticobasal degeneration (CBD), often mimic PD in the 
first years after onset [1]. Essential tremor (ET) can also 
be a challenge to differentiate from PD in the early  
stages [3]. Studies suggest that olfactory function is 
mildly impaired in MSA, CBD and PSP [4-6] and is normal 
among patients with ET [7].
Several tests have been developed to examine the 
olfactory function. The psychophysical test is the easiest 
and fastest test. It examines the ability to identify, de-
tect, discriminate and memorise odours [2].
In general, two psychophysical tests are widely used 
[2]. In the USA, the University of Pennsylvania Smell 
Identification Test (UPSIT) [8] is the most common, and 
in Europe the Sniffin’ Sticks 16 (SS-16) [9] is the most 
common [10]. The UPSIT consists of 40 odorants at the 
supra threshold level. For each odorant, the patient is 
required to choose the correct answer among four alter-
natives. Several versions of the UPSIT have been devel-
oped, e.g. the Brief Smell Identification Test, which is a 
short version with only 12 items developed for cross- 
cultural use [11]. The SS-16 consists of three parts: 
threshold, discrimination and identification. In each 
part, the subject scores 0-16 points, and the final TDI 
score, which is the sum of all three scores, is calculated 
[9]. The identification part of SS-16, called Sniffin’ Sticks 
odour Identification Test (SIT), is often used separately. 
The test consists of 16 pens filled with common odor-
ants, and the patient is required to choose between four 
alternatives [10]. Many of the tests are modified and 
translated to the culture in which they are used as cul-
tural differences may influence which odours people 
know [12-14], and for some cultures new tests have 
been developed, e.g. the Odour Stick Identification Test 
for Japanese (OSIT-J) [15].
Several studies have suggested that olfactory test-
ing is a valuable tool in the process of diagnosing PD [16-
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KEY POINTS
• Olfactory dysfunction is one of the most frequent non-motor symp-
toms in Parkinson’s disease
• Olfactory testing can be a valuable ancillary tool in diagnosing Parkin-
son’s disease
• Three out of five studies found a specificity > 80% in distinguishing 
Parkinson’s disease from a pool of conditions that mimic Parkinson’s 
disease
• The Sniffin’ Stick identification test is the most usable olfactory test 
in a busy clinical setting.
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18]. According to the new MDS criteria, a test can be 
used as an ancillary diagnostic tool if it has a specificity > 
80% in differentiating PD from other parkinsonian condi-
tions in most studies. Currently olfactory test and meta-
iodobenzylguanidine scintigraphy meet these criteria 
[19].
The aim of this study was to investigate how olfac-
tory tests can be used clinically in the process of diag-
nosing PD by focusing on the following four parameters: 
1. The ability of the olfactory tests to distinguish be-
tween idiopathic Parkinson's disease (IPD) and 
healthy controls (HC)
2. The ability of the tests to distinguish between IPD 
and diseases that mimic IPD
3. How the tests could be used and in which settings
4. The quality of the individual tests. 
METHODS
This article is based on a systematic review of the litera-
ture published before 8 March 2017. The search was 
conducted in PubMed on 8 March 2017 with the follow-
ing search terms: (olfactory dysfunction OR olfactory de-
ficiency OR hyposmia OR anosmia OR olfaction) AND 
(Parkinson* OR Parkinson's disease OR Parkinson dis-
ease OR neurodegeneration) AND (diagnostic test OR ol-
factory test OR odour test).
A total of 358 articles were found, and titles and ab-
stracts were screened using the online screening tool 
Covidence. A total of 230 articles were excluded due to 
irrelevance. A full text screening was conducted on the 
remaining 128 articles. In order to be included in the  
final study, the articles had to fulfil the following eight 
criteria: I) English or Danish written study, II) Published 
after 1st of January 1992, III) Not a meta-analysis, sys-
tematic review or editorial, IV) Inform of sensitivity, 
specificity and cut-off for an olfactory test, V) Testing 
IPD vs HC or IPD vs ET, MSA, PSP or CBD, VI) > 20 pa-
tients in the PD group, VII) The PD patients must meet 
The UK Parkinson’s Disease Society Brain Bank criteria 
[1], VIII). The olfactory test should either be SS-16, 
UPSIT, OSIT-J or a modified version of one of these.  
A total of 102 articles did not meet these criteria and 
were excluded. 
The reference lists of the remaining 26 studies were 
analysed for potential inclusion of studies not found in 
the initial search; this led to addition of one extra article. 
Accordingly, 27 articles were included in the final study 
for further analysis (see Figure 1). MBJ and TN separ-
ately screened all articles. In case of disagreement about 
the potential inclusion of an article, the article in ques-
tion was debated in plenum and a final decision was 
made. 
RESULTS
Identification of Parkinson’s disease from  
healthy controls
Twenty of the included studies analysed olfactory test 
by comparing IPD to HC, and predicted the diagnostic 
value. Sensitivities varied from 61% [20] to 95% [16], 
and specificities from 66% [21] to 96% [22]. Calculation 
of the mean, without weighting the studies, yielded a 
sensitivity of 83% and a specificity of 84%. Table 1 sum-
marizes the characteristics, sensitivity and specificity for 
each study, and Figure 2 illustrates sensitivities and spe-
cificities.  
Two studies used SS-16 to differentiate PD from HC. 
Krismer et al [16] found a sensitivity of 95% and a speci-
ficity of 95.1%. They found the area under the curve 
(AUC) for the receiver-operating characteristic curve for 
SS-16 to be 0.96, whereas the individual AUC for identifi-
FIGURE 1
Flow chart presenting the article selection process.
Articles identified by data-
base searching (n = 358)
Title and abstract screening 
(n = 358)
Full text screening (n = 128)
Studies included in the final 
systematic review (n = 27)
• Other language than 
 English and Danish (n = 5)
• Published before 1992  
(n = 5)
• Review, meta-analysis and 
editorials (n = 13)
• No sensitivity, specificity 
and cut-off values for 
 olfactory test ( n = 60)
• Not testing IPD versus HC 
or IPD versus ET, MSA, PSP 
or CBD (n = 7)
• < 20 patients (n = 2)
• Incorrect diagnostic 
 criteria (n = 9)
• Incorrect olfactory test  
(n = 1)
Total = 102
Excluded due to irrelevance 
(n = 230)
Included following manual 
review of references (n = 1)
IPD versus DD (n = 10)
IPD versus HC (n = 20)
CBD = corticobasal degeneration; DD = differential diagnosis; ET = essen-
tial tremor; HC = healthy controls; IPD = idiopathic Parkinson’s disease; 
MSA = multiple system atrophy; PSP = progressive supranuclear palsy.
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cation, discrimination and threshold was 0.94, 0.87 and 
0.84, respectively. Boesveldt et al [22] found a sensitivity 
of 81% and a specificity of 96%. They found AUC to be 
0.94, identification 0.91, discrimination 0.83 and thresh-
old 0.90. They found that identification combined with 
threshold significantly improved the AUC compared with 
identification alone.  
The remaining studies used identification tests 
alone, seven used the UPSIT and nine used the SIT. 
Several studies gave multiple results at different cut-
offs. Four studies used a shorter version of the SIT with 
12 odours (SIT-12), and one used a shorter version of 
the UPSIT. Casjens et al [20] analysed each odour from 
the SIT, and found that peppermint, anise and coffee 
best differentiated PD from HC, and calculated sensitiv-
ity and specificity for these three odours. Bohnen et al 
[23] did the same based on the UPSIT, and found ba-
nana, liquorice and dill pickle to best differentiate PD 
from HC. 
Gender was a significant independent predictor in 
six studies [6, 24-28] with increased olfactory score in fe-
males compared with males, whereas six studies found 
no significant difference [7, 20, 21, 29-31]. 
Progression of olfactory dysfunction
Fourteen studies found increased age to be a significant 
independent predictor of decreased olfactory score [4, 
6, 20, 21, 24-29, 32-35], whereas three studies found 
that it was not significant [7, 30, 31]. 
Olfactory dysfunction as a marker of progression
Casjens et al [20] and Rodriguez-Violante et al [34] 
found Hoehn & Yahr stage to be a significant indepen-
dent predictor of the olfactory score, and Rodriguez- 
Violante et al [34] also found disease duration to be a 
significant predictor. Five studies did not find disease 
duration and severity to be significant independent pre-
dictors [17, 26, 28, 32, 36], and four studies found that 
only disease duration was not a significant independent 
predictor [16, 18, 23, 31]. Boesveldt et al [28] found the 
ability to discriminate odours to be reduced when the 
disease duration increases, but identification remains 
the same.
Separating Parkinson’s disease from  
atypical Parkinson’s disease
Five studies analysed the ability of the tests to distin-
guish PD from a pool of several diagnoses that mimic PD 
[4, 16, 18, 29, 32] (see Table 2), and found sensitivities 
from 75% to 92% and specificities from 70% to 85%. 
Mahlknecht et al [18] applied a lower cut-off and found 
an increase in both sensitivity and specificity.
Several studies analysed the ability of the olfactory 
tests to distinguish PD from one specific type of atypical 
PD. Three studies analysed the ability to distinguish PD 
from MSA [16, 18, 37], and found sensitivities from 74% 
to 92% and specificities from 78% to 87%. Three studies 
analysed the ability to distinguish PD from PSP [6, 16, 
18] and found sensitivities from 75% to 92% and specifi-
FIGURE 2
Overview of sensitivities (dark blue) and specificities (light blue) of the individual studies testing idiopathic Parkinson's disease against healthy controls. The studies are listed by olfac-
tory test and decreasing specificity. The dotted line illustrates the 80% limit. 
B-SIT = Brief Smell Identification Test; OSIT-J = Odour Stick Identification Test for Japanese; SI = Sniffin’ Sticks Odour Identification Test; SS-16 = Sniffin’ Sticks 16; UPSIT = University of 
Pennsylvania Smell Identification Test.
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TABLE 1
Overview of the included studies testing the ability to distinguish Parkinson’s disease from healthy controls. The studies are sorted by olfactory test, and the references are subdivided 
by decreasing specificity.
Continues
Olfactory test  
Reference
Specificity,
%
Sensitivity,
%
PD patients, 
n (♂/♀)
Controls, n 
(♂/♀)
H&Y-stage: 
1 + 2, 3, ≥ 4, 
% (mean)
Disease 
 duration, 
mean, yrs Cut-off Comments
SS-16
Boesveldt et al, 2009, Nether-
lands [22]
96 81 52 (29/23) 50 (27/23) 92, 8, 0 6, 7 Z-score: 
–0.736
-
Krismer et al, 2017, Austria 
[16]
95.1 95 20 (13/7) 41 (23/18) (2.3) 5, 9 23.875 Similar results were found by analysing pa-
tients with disease duration < 3 yrs
SIT
Krismer et al, 2017, Austria 
[16]
97.6 70 20 (13/7) 41 (23/18) (2.3) 5, 9 ≤ 8 Cut-off value with optimal specificity
78 95 ≤ 11 Cut-off value with optimal sensitivity
Silveira-Moriyama et al, 2008, 
Brazil [24]
89 81.1 106 (71/35) 118 
(103/15)
- 11, 4 ≤ 9: < 60 yrs
≤ 8: ≥ 60 yrs
Subjects were tested by either the SIT, UP-
SIT or both tests
It was not stated how many subjects were 
tested by each test
Age was a significant variable
Mahlknecht et al, 2016, Aus-
tria & Italy [18]
86.5 92.1 134 (84/50) 336 
(156/180)
(2.4) 6, 2 ≤ 10 Validation cohort, Centre A
Similar results were found by analysing pa-
tients with disease duration < 3 yrs
Followed for 24 mo.s to validate the diag-
nosis
86.1 85.9 134 (84/50) 336 
(156/180)
(2.4) 6, 2 ≤ 10 Discovery cohort, Centre A
82 83.3 400 
(249/151)
150 (87/63) (2.6) 11, 4 ≤ 10 Validation cohort, Centre B
Santin et al, 2010,  Brazil  [27] 85.7 88.2 51 (29/22)
70 (38/32) (2.2)
5, 9 ≤ 9 Analysed late onset: > 45 yrs
Age and gender were significant variables
78.6 63.2 19 (9/10) 9, 7 ≤ 10 Analysed early onset: < 45 yrs
Silveira-Moriyama et al, 2009, 
Brazil  [33]
85.5 90.4 193 
(115/78)
157 (93/64) - 10, 2 ≤ 10 The SIT tested on 115 PD and 83 HC of the 
study population
Boesveldt et al, 2008, Nether-
lands  [28]
82 83 404 
(253/151)
150 (87/63) - - 10.5 Age and gender were significant variables
Disease duration and disease severity 
were not significant variables
Chen et al, 2012, China  [31] 81 86 110 (66/44) 110 (66/44) 84, 16, 0 4, 3 9.5 Age and gender were not significant 
 variables
Rodríguez-Violante et al, 
2014, Mexico  [21]
71.2 77.8 99 (64/35) 99 (64/35) 70, 25, 5 7, 3 ≤ 9 Age was a significant variable
Gender was not a significant variable
SIT-12
Silveira-Moriyama et al, 2009, 
Sri Lanka  [30]
93 91 89 (50/39) 100 (52/48) - 6, 4 ≤ 8 Used the 12 odours from the SIT for which 
> 50% of the HC had answered correctly
Age and gender were not significant 
 variables
Chen et al, 2012, China  [31] 85 87 110 (66/44) 110 (66/44) 84, 16, 0 4, 3 7.5 Used the SIT and excluded the 4 odours 
without a significant difference between 
the score of PD and HC
López Hernández et al, Spain 
2015 [38]
83 70 30 (22/8) 47 (26/21) - 2, 1 < 8 -
Huang et al, 2016, China  [42] 81.5 90.7 54 (43/11) 54 (43/11) 81, 19, 0 2, 7 7.5 Followed for ≥ 24 mo.s to validate the di-
agnosis
SIT-3
Casjens et al, 2013,  Germany 
[20]
88 61 148 (78/70) 148 (81/67) - - ≤ 1 Used the 3 odours with the highest sensi-
tivity from the SIT
Age, disease duration and severity were 
significant variables
Gender was not a significant variable
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cities from 65% to 74%. ET was also included, and four 
studies analysed the ability of the tests to differentiate 
PD from ET [7, 18, 36, 38], and found sensitivities be-
tween 62% and 92% and specificities between 67% and 
96%. 
DISCUSSION
All included studies found a significant correlation be-
tween olfactory function and IPD, but there was a wide 
range of sensitivities and specificities. 
Identification of Parkinson’s disease from  
healthy controls
Krismer et al [16] found the best ability to distinguish 
IPD from HC, but they only included 20 patients. The 
study was based on two independent cohorts, one 
which found specificity-weighted cut-off and one which 
determined the accuracy. Patients were followed for 24 
months to ensure diagnosis. Mahlknecht et al [18] and 
Boesveldt et al [28] both had populations counting more 
than 400 patients, and both found sensitivities and spe-
cificities for SIT of approximately 83% and 82%. Mahl-
knecht et al [18] also made a prospective cohort at three 
independent centres, while Boesveldt et al [28] made a 
case-control study. 
The study with largest patient population and with 
the most powerful study design also reported results 
closest to the mean of all included studies, which sup-
ports these results. 
Rodríguez-Violante et al [21] performed a case- 
TABLE 1 CONTINUED
B-SIT = Brief Smell Identification Test; H&Y = Hoehn & Yahr; HC = healthy controls; OSIT-J = Odour Stick Identification Test for Japanese; PD = Parkinson’s disease; SIT = Sniffin’ Sticks 
Odour Identification Test; SS-16 = Sniffin’ Sticks 16; UPSIT = University of Pennsylvania Smell Identification Test;
Olfactory test  
Reference
Specificity,
%
Sensitivity,
%
PD patients, 
n (♂/♀)
Controls, n 
(♂/♀)
H&Y-stage: 
1 + 2, 3, ≥ 4, 
% (mean)
Disease 
 duration, 
mean, yrs Cut-off Comments
UPSIT
Bohnen et al, 2008, USA  [43] 93.3 80 45 (31/14) 45 (31/14) 98, 2, 0 3, 5 27 -
Picillo et al, 2014, Italy [26] 88.2 82 68 (40/28) 61 (27/34) (1.6) 4, 8 ≤ 21 Age and gender were significant variables
Disease duration and severity were not 
significant variables
Silveira-Moriyama et al, 2009, 
Brazil [33]
84.6 85 193 
(115/78)
157 (93/64) - 10, 2 ≤ 23: ≥ 60 
yrs
≤ 28: < 60 
yrs
Age was a significant variable
UPSIT examined on 167 PD and 130 HC of 
the study population
Silveira-Moriyama et al, 2008, 
Brazil [24]
83.5 82.1 106 (71/35) 118 
(103/15)
- 11, 4 ♀
≤ 29: < 60 
yrs
≤ 25: ≥ 60 
yrs
Age and gender were significant variables
♂
≤ 19: < 60 
yrs
≤ 16: ≥ 60 
yrs
Yu et al, 2014, Taiwan [35] 70 86 30 (15/15) 161 (81/80) 100, 0, 0 < 2 29.5 Age was a significant variable
Rodríguez-Violante et al, 
2014, Mexico [25]
68.5 79.7 138 (81/57) 175 (85/90) 73, 22, 5 7, 4 ≤ 25 Age and gender were significant variables
Rodríguez-Violante et al, 
2014, Mexico [21]
66 82 100 (55/45) 100 (55/45) 73, 20, 7 7, 4 ≤ 25 -
B-SIT
Rodríguez-Violante et al, 
2011, Mexico [34]
85.7 71.4 70 (41/29) 70 (41/29) 61, 34, 5 6, 7 ≤ 9: < 60 yrs
≤ 7: ≥ 60 yrs
Age, disease duration and severity were 
significant variables
UPSIT-3
Bohnen et al, 2007, USA [23] 96.3 70.3 27 (20/7) 27 (20/7) 96, 4, 0 2, 5 ≤ 1 Used the 3 odours from the UPSIT with 
the highest sensitivity
Disease duration was not a significant vari-
able
OSIT-J
Izawa et al, 2012, Japan [17] 78.1 84.8 33 (17/16) 32 (17/15) - 4, 6 ≤ 8 Disease duration and severity were not 
significant variables
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TABLE 2
Overview of the included studies testing the ability to distinguish Parkinson’s disease from other parkinsonian conditions: the ability to distinguish from multiple system atrophy, the 
ability to distinguish from progressive supranuclear palsy, the ability to distinguish from essential tremor, and the ability to distinguish from a pool of conditions that mimic idiopathic 
Parkinson’s disease. 
Continues 
Reference
Differen-
tial diag-
nosis
PD DD
Test Cut-off
Sens,
%
Spec,
% Commentsn (♂/♀)
H&Y-
stage, 
mean 
(%)
duration, 
mean, 
yrs n (♂/♀)
H&Y-
stage, 
mean
duration, 
mean, 
yrs
Differentiating from MSA
Mahlknecht et al, 2016, 
Austria/Italy [18]
MSA 134 
(84/50)
2.4 6.2 23 
(11/12)
3.3 4.2 SIT ≤ 9 84.1 87 Validation cohort, Cen-
tre A
Similar results were 
found by analysing pa-
tients with a disease 
duration < 3 yrs
Followed for 24 mo.s 
to validate the diagno-
sis
≤ 10 92.1 78.3 Validation cohort, Cen-
tre A
Kikuchi et al, 2011,  Japan 
[37]
MSA 42 (18/24) - 2.7 42 
(24/18)
- 2.6 OSIT-J 8.5 73.81 85.71 Final diagnosis was 
confirmed after 2 yrs 
of follow-up
Krismer et al, 2017, Aus-
tria [16]
MSA 47 (31/16) 2.5 7 23 
(11/12)
3 4.2 SS-16 23.875 78.7 78.3 Similar results were 
found by analysing pa-
tients with a disease 
duration < 3 yrs
Differentiating from PSP
Krismer et al, 2017, 
 Austria [16]
PSP 47 (31/16) 2.5 7 23 (16/7) 3 3.2 SS-16 23.875 78.7 73.9 -
Mahlknecht et al, 2016, 
Austria/Italy [18]
PSP 134 
(84/50)
2.4 6.2 23 (16/7) 3 3.1 SIT ≤ 9 84.1 73.9 Validation cohort, Cen-
tre A≤ 10 92.1 65.2
Silveira-Moriyama et al, 
2010, United Kingdom [6]
PSP 86 (49/37) - 10.4 36 
(20/16)
- 4.8 UPSIT 18 75 65.1 Age and gender were 
significant variables 
Differentiating from ET
Chen et al, 2012, China 
[36]
ET 37 (26/11) (1 + 2: 
76; 
> 2: 24)
3.6 26 
(14/12)
- 12 SIT 9.5 62.2 96.2 Disease duration and 
severity were not sig-
nificant variables
Shah et al, 2007, United 
Kingdom [7]
ET/
healthy 
controls
64 (44/20) - 4.8 304 
(111/193)
- Familial 
ET: 24.2
Non-fa-
milial 
ET: 12.4
UPSIT < 25 83 94 Gender was not a sig-
nificant variable
PD patients was diag-
nosed with tremor 
dominant PD
Mahlknecht et al, 2016, 
Austria/Italy [18]
ET 134 
(84/50)
2.4 6.2 29 
(12/17)
- 18.7 SIT ≤ 9 84.1 89.7 -
≤ 10 92.1 82.8
López Hernández et al, 
2015, Spain [38]
ET 30 (22/8) - 2.1 21 (15/6) 6.3 SIT < 8 70 66.7 -
control study and found the lowest specificity. The study 
included 100 patients, and used the Spanish UPSIT on a 
Mexican population, which could partly explain the low 
specificity because the odours were not familiar to the 
Mexican population. 
Two studies [16, 22] used the entire SS-16, which 
includes odour identification, discrimination and thresh-
old. The results were among the best with regard to sen-
sitivities and specificities. Odour identification is the ol-
factory feature that is most frequently impaired in PD, 
and the combination of several features only improved 
the quality of the SS-16 a little [16, 28]. Only Boesveldt 
et al [22] found that a combination of threshold and 
identification improved the AUC compared with the 
identification test alone, but the study was small and 
they did not follow the patients over time to ensure di-
agnosis. Only two studies used the SS-16. More studies 
are therefore required, but the results indicate that the 
SS-16 is only slightly better than identification alone. 
Identification test is significantly less time consuming 
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TABLE 2 CONTINUED
APS = atypical parkinsonian syndromes; CBD = corticobasal degeneration; DD = differential diagnosis; ET = essential tremor; H&Y = Hoehn & Yahr; MDD = major depressive disorder 
with motor slowing; MSA = multiple system atrophy; OSIT-J = Odour stick identification test for Japanese; PD = Parkinson’s disease; PSP = progressive supranuclear palsy; ; Sens = sensi-
tivity; Spec = specificity; SIT = Sniffin’ Sticks Odour Identification Test; SS-16 = Sniffin’ Sticks 16; UPSIT = University of Pennsylvania Smell Identification Test; VP = vascular parkinsonism.
than the entire SS-16 [16]; and in a busy clinical setting, 
the use of an identification test would be preferable. 
According to Figure 2, the sensitivities between the 
SIT and the UPSIT do not vary much, but the figure sug-
gests a slightly lower specificity for the UPSIT. A few 
studies used smaller versions of the tests, and these 
studies indicate no inferior ability to diagnose PD, but 
this issue remains controversial due to the low number 
of studies. 
Casjens et al [20] and Bohnen et al [23] analysed 
three odours they found to be the best to discriminate 
PD from HC. The tested subjects were from Germany 
and USA. None of the odours was the same in the two 
studies, probably because the familiar odours are differ-
ent in each country. The low sensitivities in both studies 
may be the result of only using three odours. According 
to our study, the UPSIT or the SIT is the most useful ol-
factory test. Before using the olfactory test in the clinic, 
the odours should be tested and validated in the popula-
tion in which they are intended to be used, and odours 
with a low recognisability in the healthy population 
should be substituted with more familiar odours. 
Comparing the included studies, we find no correla-
tion between the cut-off scores and the sensitivity and 
specificity. When choosing a low cut-off, we would ex-
pect a higher proportion of subjects to be classified as 
healthy, resulting in a higher specificity. The test should 
be used as a diagnostic tool and the cut-off should be 
adjusted to a specificity-balanced cut-off score.  
The influence of gender on the olfactory scores was 
not consistent. Silveira-Moriyama et al [24] was the only 
study with gender-adjusted cut-off, and they did not find 
a better diagnostic value than the studies with a general 
cut-off value.
Progression of olfactory dysfunction
With increasing age comes a decrease in olfactory func-
tion in healthy people [39]. Most included studies found 
a negative correlation between age and olfactory func-
tion. The three studies [24, 33, 34] that used different 
cut-offs for different age groups did not find better di-
agnostic value than the studies using a general cut-off.  
The lowest sensitivity was found by Santin et al [27] 
who tested subjects below 45 years of age. The same 
Reference
Differen-
tial diag-
nosis
PD DD
Test Cut-off
Sens,
%
Spec,
% Commentsn (♂/♀)
H&Y-
stage, 
mean 
(%)
duration, 
mean, 
yrs n (♂/♀)
H&Y-
stage, 
mean
duration, 
mean, 
yrs
Differentiating from several DD
Wenning et al, 1994, Eng-
land [4]
MSA/
PSP/CBD
118 
(58/60)
- - 51 
(34/17)
- - UPSIT 25 77 85 Age was a significant 
variable
Mahlknecht et al, 2016, 
Austria/Italy [18]
MSA/
PSP/ET
134 
(84/50)
2.4 6.2 75 
(39/36)
3.2 8 SIT ≤ 9 84.1 84 -
Wolz et al, 2014, 
 Germany [29]
ET, MSA 
and 
other 
tremor 
disorders
167 
(116/51)
- - 132 
(73/59)
- - SIT 11 79 80.3 Age was a significant 
variable
Gender was not a sig-
nificant variable
If there was doubt 
about the diagnosis, 
DaTSCAN was used to 
determine the final di-
agnosis
SS-16 25 76 78.8 -
Krismer et al, 2017, Aus-
tria [16]
PSP/MSA 47 (31/16) 2.5 7 46 
(27/19)
3 3.7 SS-16 23.875 78.7 76.1 -
Mahlknecht et al, 2016, 
Austria/Italy [18]
MSA/
PSP/ET
134 
(84/50)
2.4 6.2 75 
(39/36)
3.2 8 SIT ≤ 10 92.1 76 -
Busse et al, 2012, 
 Germany [32]
APS/VP/
ET/MDD
385 
(257/128)
3 9. 9 132 
(67/65)
2 6 SIT-12 < 8 75 70 Age was a significant 
variable
Disease duration and 
severity were not sig-
nificant variables
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study tested subjects above 45 years of age and found a 
markedly increased sensitivity and specificity (see Table 
1). It seems that different cut-offs for different age 
groups do not increase the ability of the olfactory tests 
to diagnose PD, but the tests are more precise among 
older people because of a non-parallel reduction in ol-
factory score. 
Olfactory dysfunction as a marker of progression
Of the included studies only Rodriguez-Violante et al 
[34] found a significant correlation between both dis-
ease stage and disease duration. Furthermore, Casjens 
et al [20] found disease stage to be correlated with ol-
factory score. Both were case-control studies with 70 
and 148 patients, respectively. Five studies found no 
correlation between the olfactory identification score 
and the disease stage or duration [17, 26, 28, 32, 36]. 
Busse et al [32] was the only prospective cohort study 
where 632 patients with clinical parkinsonian symptoms 
were followed. The study found no correlation with ei-
ther disease stage or duration, but a mild progression of 
hyposmia was found when comparing baseline and five-
year follow-up data. 
Boesveldt et al [28] indicated that the ability to dis-
criminate odours was reduced by increased disease dur-
ation, also demonstrated by Tissingh et al [40]. These 
studies indicate that the identification test is correlated 
neither with disease stage nor with duration, and there-
fore is not a good prognostic factor; however, more pro-
spective studies that analyse the olfactory function over 
time are needed, and special attention should be devot-
ed to analysing other aspects than identification. The 
identification test, however, can be used as a diagnostic 
tool independently of disease duration and severity, also 
early in the disease. 
Separating Parkinson’s disease from  
atypical Parkinson’s disease
In clinical use, an important feature is the ability of a 
test to distinguish IPD from other parkinsonian con-
ditions. 
In MSA and PSP, the olfactory function is mildly im-
paired [4] and we should thus expect a lower specificity. 
Only three studies analysed MSA [16, 18, 37] and PSP [6, 
16, 18]. None of them used the same olfactory test, and 
they all used different cut-offs; therefore, the frame of 
reference is weak. Overall, the ability to differentiate IPD 
from MSA varied, but the results indicate that the tests 
are useful in separating the two groups. Regarding PSP, 
the sensitivities and specificities indicated that the abil-
ity of the tests to distinguish IPD and PSP is weaker. 
Olfactory function in ET is maintained [7], and we ex-
pected results similar to those reported in studies com-
paring PD to HC. The four studies that analysed ET re-
ported varying results, which made it difficult to draw a 
definite conclusion about the ability to differentiate be-
tween patients with PD and ET. 
Five studies compared PD against two or more  
conditions that mimic PD (see Table 2). None of these 
studies were similar in terms of the differential diagno-
ses with which PD was compared, and the number of 
differential diagnoses in the pool also varied. The largest 
study in this group was Busse et al [32] which is de-
scribed above. Patients were examined with a short ver-
sion of SIT, and a low specificity of 70% was found. 
Mahlknect et al [18] found a specificity of 76% with a 
cut-off ≤ 10. Lowering the cut-off to ≤ 9 increased the 
specificity to 84%. 
To meet the MDS criteria for the olfactory test to be 
an ancillary diagnostic tool, the test should provide a 
specificity > 80% in most studies, with a minimum of 
three studies from different centres [19]. According to 
our study, three out of five studies found a specificity > 
80% (Table 2), but the study with the strongest study de-
sign and the largest population only had a specificity of 
70%. This could indicate that with the full UPSIT or the 
SIT and with a specificity-adjusted cut-off, the olfactory 
test can be used according to the MDS criteria.
According to the MDS, the test is an ancillary test 
among many others. If the olfactory score is below the 
cut-off, the positive predictive value (PPV) will depend 
on the setting in which the test is used. In general prac-
tice, the prevalence of IPD is low, which will result in a 
low PPV. However, in a specialised neurologic clinic, the 
test could be a valuable tool since the prevalence of IPD 
is higher.
Testing olfactory function in a clinical setting.
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A strength in our study is that the screening and ex-
clusion processes were accomplished by two authors, 
which can minimize the risk of personal bias and opin-
ion. Furthermore, two authors independently went 
through all the included studies, which also increases 
the re-test ability.
A limitation of this study was that the number of 
studies using SS-16 and UPSIT was limited, which might 
lead to uncertain results. The same applies for studies 
that compare PD to other parkinsonian conditions. The 
studies had to be published after 1992 to be included in 
the final analysis. UPSIT has been used since 1984 [41], 
and with a bigger time frame, the results could have 
been stronger. We chose studies published after 1992 
because the UK PD Brain Bank Criteria were published 
that year [1]. This ensures that the population in our 
study was diagnosed according to consistent criteria. 
Hughes et al [1] studied patients diagnosed with PD, and 
found that the UK PD Brain Bank misdiagnosed 24% [1]. 
Thus, when comparing PD with parkinsonian syndromes, 
some of the PD patients might have had atypical PD, and 
the ability to distinguish PD from atypical PD might be 
higher than the one we found. Olfactory test as well as 
other tools may potentially assist early identification of 
PD, but this is beyond the scope of this review. 
CONCLUSIONS
Olfactory test can be a valuable ancillary tool in the diag-
nostic process of PD. The diagnostic value becomes 
more precise by increasing age. SS-16 seems to be the 
most precise test, but SIT is the most usable test in a 
busy clinical setting because it can be conducted quickly 
and independently of disease duration and severity. 
Sensitivities and specificities in distinguishing PD 
from MSA, PSP or ET indicate that the olfactory identifi-
cation test is a valuable ancillary tool in the diagnostic 
process of PD, but the results are weak due to the low 
number of studies. According to our study, three out of 
five studies found a specificity > 80% in distinguishing PD 
from a pool of conditions that mimic PD, which is re-
quired for an ancillary test according to the new MDS 
criteria.
Before using an olfactory test in a clinical setting, it 
is necessary to adjust the odours to the population it is 
intended for, and to find the optimal specificity-adjusted 
cut-off.
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